Zollinger-Ellison Syndrome

1. Clinical Overview

Summary

Zollinger-Ellison Syndrome (ZES) is a clinical syndrome caused by a gastrinoma—a gastrin-secreting neuroendocrine tumour (NET)—resulting in profound gastric acid hypersecretion. The syndrome is characterized by the clinical triad of severe peptic ulcer disease, gastroesophageal reflux, and diarrhea. [1]

Key Features:

• Sporadic: 75–80% of cases. Usually solitary pancreatic or duodenal tumours, potentially curable with surgical resection.
• MEN1-Associated: 20–25% of cases. Multiple gastrinomas, often microadenomas, challenging to cure surgically. [2,3]

Clinical Importance:
Although rare (incidence 0.5–2 per million per year), ZES is the most common symptomatic, functionally active gastroenteropancreatic neuroendocrine tumour (GEP-NET). Delayed diagnosis is common, with an average lag of 5–7 years from symptom onset, often due to the widespread use of proton pump inhibitors (PPIs) masking symptoms. [4,5]

Clinical Pearls

The "Paradoxical" Secretin Stimulation Test: In health, secretin inhibits gastrin release. In ZES, tumour G-cells aberrantly respond to secretin with a paradoxical rise in serum gastrin (≥120 pg/mL increase), achieving 94% sensitivity for diagnosis. [6]

Location, Location, Location: 90% of gastrinomas occur within the Gastrinoma Triangle (Passaro's Triangle):

1. Cystic duct / common bile duct junction (superior border)
2. Junction of 2nd/3rd part of duodenum (inferior border)
3. Neck of pancreas (medial border) [7]

Diarrhea Mechanism: Massive acid output (often BAO > 15 mEq/hr) overwhelms duodenal bicarbonate buffering. Low intraduodenal pH (less than 4) inactivates pancreatic lipase, causing fat malabsorption (steatorrhea) and osmotic/secretory diarrhea. Diarrhea is the sole presenting symptom in 10% of cases. [8]

Think MEN1: All patients with ZES should be screened for MEN1 (check serum calcium, PTH, prolactin). Conversely, 20–60% of MEN1 patients develop gastrinomas during their lifetime. [9]

---

2. Epidemiology

Demographics

Associations

• Sporadic ZES: 75–80%

• MEN1-Associated ZES: 20–25%

  • MEN1 = Menin gene mutation (chromosome 11q13)
  • Autosomal dominant inheritance
  • "Triad: Parathyroid adenomas (90%), pancreatic NETs (60%), pituitary adenomas (30%) [9]"

• Other Rare Associations:

  • Neurofibromatosis type 1 (NF1)
  • Von Hippel-Lindau (VHL) syndrome (rare reports)

---

3. Aetiology & Pathophysiology

Normal Gastric Acid Regulation

Physiological Gastrin Axis:

1. Food intake stimulates antral G-cells → Release gastrin into bloodstream
2. Gastrin binds CCK-B receptors on parietal cells → ↑ H⁺ secretion
3. Gastrin also stimulates enterochromaffin-like (ECL) cells → Release histamine → Further ↑ acid via H₂ receptors
4. Negative feedback: Low intragastric pH (≤3) → Inhibits G-cells via somatostatin (D-cells) [12]

Pathophysiology of ZES

Autonomous Gastrin Hypersecretion:

• Gastrinoma cells produce and secrete gastrin independent of feedback inhibition
• Fasting serum gastrin often > 1000 pg/mL (normal less than 100 pg/mL)
• Basal acid output (BAO) > 15 mEq/hr (normal less than 5 mEq/hr); can exceed 50 mEq/hr in severe cases [13]

Cellular Consequences:

1. Parietal Cell Mass Expansion: Chronic hypergastrinemia → Parietal cell hyperplasia → ↑ acid-secreting capacity
2. ECL Cell Hyperplasia: Chronic gastrin stimulation → ECL proliferation → Risk of gastric carcinoid formation (especially in MEN1) [14]
3. Mucosal Damage: Excessive acid → Peptic ulcers (duodenum > stomach > jejunum), oesophagitis, diarrhea

Molecular Pathophysiology:

• Gastrinomas are well-differentiated neuroendocrine tumours (NETs), typically grade 1 or 2 (WHO classification)
• Express somatostatin receptors (SSTR2 > SSTR5), enabling functional imaging with somatostatin analogue tracers (e.g., Ga-68 DOTATATE PET) [15]
• 60–90% are malignant, with slow but relentless growth; liver metastases in 30–40% at diagnosis [16]

Location and Tumour Characteristics

---

4. Clinical Presentation

Symptoms

Classic Triad (not always complete):

1. Peptic Ulcer Disease (90%):

   • Severe, recurrent, or refractory to standard PPI therapy
   • Unusual locations: Post-bulbar duodenum (50%), jejunum (10%)
   • Multiple ulcers (30%)
   • Complications: Perforation (7%), bleeding (25%) [17]

2. Diarrhea (50–70%):

   • Watery, high-volume (> 1 L/day in severe cases)
   • Steatorrhea (greasy, malodorous stools) due to lipase inactivation
   • Sole presenting symptom in 10% of cases
   • Often attributed to IBS or infection initially [8]

3. Gastroesophageal Reflux Disease (GERD) (60%):

   • Severe heartburn, regurgitation
   • Erosive oesophagitis, Barrett's oesophagus
   • Strictures in advanced cases

Less Common Symptoms:

• Weight loss (20%): Due to malabsorption and reduced oral intake
• Nausea and vomiting
• Abdominal pain (epigastric, colicky if ulcer-related)

Atypical Presentations:

• Diarrhea alone (mimics IBS, celiac disease, or inflammatory bowel disease)
• Unexplained vitamin B12 or iron deficiency anemia
• Hypoalbuminemia (protein-losing enteropathy from acid-induced mucosal injury)

Signs

Physical examination is often unremarkable unless complications or MEN1 stigmata present:

• Epigastric tenderness (ulcer-related)

• Weight loss, cachexia (advanced malabsorption)

• Signs of MEN1 (if associated):

  • Hypercalcemia symptoms: Renal stones, bone pain, depression ("stones, bones, moans")
  • Visual field defect (bitemporal hemianopia from pituitary macroadenoma)
  • Lipomas, facial angiofibromas (cutaneous manifestations)

• Signs of Complications:

  • Peritonitis (rigid abdomen, guarding) → Perforated ulcer
  • Melaena or hematochezia → GI bleeding
  • "Signs of liver metastases: Hepatomegaly, jaundice (rare)"

---

5. Differential Diagnosis

Hypergastrinemia is not exclusive to ZES. Key differentials include:

Key Diagnostic Principle: Hypergastrinemia + Low Gastric pH (less than 2) = Consider ZES
Hypergastrinemia + High Gastric pH (> 4) = Achlorhydria (e.g., pernicious anemia, PPI use)

---

6. Investigations

Biochemical Diagnosis

1. Fasting Serum Gastrin (FSG)

Procedure:

• Measure after 12-hour overnight fast
• CRITICAL: Stop PPIs for 2 weeks and H2-receptor antagonists for 48 hours before testing (PPIs induce hypergastrinemia by causing achlorhydria)

Interpretation:

2. Gastric pH Measurement

• Measured via nasogastric tube or during endoscopy
• pH less than 2: Confirms acid hypersecretion → ZES likely
• pH > 4: Achlorhydria → Consider atrophic gastritis, PPI effect [18]

3. Secretin Stimulation Test (Gold Standard Provocative Test)

Indications:

• FSG 110–1000 pg/mL (equivocal range)
• Clinical suspicion despite FSG less than 1000 pg/mL

Procedure:

1. Measure baseline fasting serum gastrin
2. Administer secretin 2 μg/kg IV bolus
3. Measure serum gastrin at 2, 5, 10, 15, 20, 30 minutes post-injection

Interpretation:

• Positive: Gastrin rise ≥120 pg/mL from baseline within 15 minutes
• Sensitivity: 94%; Specificity: 100% [6]
• False positives rare but reported with PPI use; ideally perform off PPIs [19]

4. Basal Acid Output (BAO)

• Measures gastric acid secretion during fasting state
• ZES: BAO > 15 mEq/hr (normal less than 5 mEq/hr)
• Less commonly performed now due to widespread PPI availability masking hypersecretion [13]

5. Serum Chromogranin A (CgA)

• Non-specific NET marker; elevated in 70–80% of ZES
• Useful for monitoring disease burden and recurrence post-surgery
• Caution: Also elevated with PPI use, renal failure, atrophic gastritis [20]

Tumour Localisation Imaging

Objectives:

1. Localize primary gastrinoma
2. Assess for metastatic disease (liver, lymph nodes, bone)
3. Guide surgical planning

First-Line Imaging

1. Gallium-68 DOTATATE PET/CT (Somatostatin Receptor Imaging):

   • Gold standard functional imaging for gastrinomas
   • Sensitivity: 90–95% for primary tumours, 95–100% for metastases
   • Exploits SSTR2/5 expression on NET cells [15]

2. Multiphasic CT or MRI Abdomen/Pelvis:

   • Detects tumours > 1 cm
   • Assesses liver metastases
   • Pancreatic protocol CT: Arterial, portal venous, delayed phases

Second-Line / Adjunct Imaging

3. Endoscopic Ultrasound (EUS):

   • Excellent for small pancreatic head and duodenal wall tumours (less than 1 cm)
   • Sensitivity: 75–90% for pancreatic gastrinomas; 50% for duodenal (often very small)
   • Allows fine-needle aspiration (FNA) for cytology [21]

4. Octreotide Scan (Somatostatin Receptor Scintigraphy, SRS):

   • Historical standard (now largely replaced by Ga-68 DOTATATE PET)
   • Lower sensitivity (~70% for primary tumours)

5. Selective Arterial Secretin Injection (SASI):

   • Highly specialized, invasive test
   • Secretin injected into arteries supplying pancreas/duodenum during angiography
   • Gastrin measured in hepatic vein; rise localizes tumour to vascular territory
   • Sensitivity > 90% but rarely used due to complexity [22]

Endoscopy

Upper GI Endoscopy (Oesophagogastroduodenoscopy, OGD):

• Findings:

  • "Peptic ulcers: Duodenum (75%), post-bulbar (50%), jejunum (10%), stomach (25%)"
  • Multiple ulcers (30%)
  • Severe oesophagitis, Barrett's oesophagus
  • Prominent gastric folds (due to acid-induced hyperplasia)

• Biopsies:

  • "Gastric body: ECL cell hyperplasia, parietal cell hyperplasia"
  • "Duodenum: May identify small submucosal gastrinomas"

Screening for MEN1

All patients with ZES should undergo MEN1 screening:

• Serum calcium, PTH (hyperparathyroidism in 90% of MEN1)
• Prolactin, IGF-1 (pituitary adenomas)
• Fasting glucose, insulin (insulinomas)
• Genetic testing: MEN1 gene sequencing if clinical suspicion or family history [9]

---

7. Management

Overview

Management strategies depend on:

1. Tumour characteristics: Sporadic vs. MEN1-associated; localized vs. metastatic
2. Acid hypersecretion control: Essential in all patients
3. Surgical curability: Feasible in sporadic, localized disease

Management Algorithm

        SUSPECTED ZES
    (Recurrent Ulcers / Diarrhea)
                ↓
    FASTING GASTRIN + pH CHECK
    (Stop PPIs ≥2 weeks prior!)
      ┌─────────┴─────────┐
   GASTRIN HIGH       GASTRIN HIGH
   pH LOW (less than 2)        pH HIGH (> 4)
      ↓                   ↓
     ZES              ACHLORHYDRIA
  (Confirm with       (Pernicious Anemia,
   Secretin Test)      Atrophic Gastritis)
      ↓
    LOCALISE TUMOUR
    (Ga-68 DOTATATE PET/CT + EUS)
      ↓
    SCREEN FOR MEN1
    (Ca²⁺, PTH, Prolactin, Genetic Testing)
      ↓
   ┌──────────┴──────────┐
  SPORADIC            MEN1-ASSOCIATED
 (80% of cases)       (20% of cases)
      ↓                     ↓
  ┌───┴───┐           MEDICAL MANAGEMENT
LOCALIZED  METASTATIC   (High-Dose PPI)
  ↓           ↓          Rarely Surgical
SURGICAL   MEDICAL      (if dominant tumour > 2 cm)
RESECTION  CONTROL
(Curative) (Palliative)

Medical Management: Acid Suppression

Objective: Normalize acid output (BAO less than 10 mEq/hr; less than 5 mEq/hr if prior ulcer complications)

Proton Pump Inhibitors (PPIs)

First-Line:

• Omeprazole: 60 mg BD initially; titrate to symptom control

• Lansoprazole: 60 mg BD

• Esomeprazole: 40 mg BD

• Pantoprazole: 80–120 mg BD (IV formulation available)

• Dose requirements 2–10 times higher than standard GERD dosing

• 90–95% symptom control achievable [23]

• Monitor clinical response and consider BAO measurement (if available) to guide dosing

• Indefinite therapy required if not surgically cured

Side Effects of Long-Term High-Dose PPIs:

• Hypomagnesemia (monitor Mg²⁺ annually)
• Increased fracture risk (osteoporosis screening)
• Vitamin B12 deficiency (annual B12 levels)
• Clostridium difficile infection risk
• Chronic kidney disease (rare association)

H2-Receptor Antagonists (Largely Obsolete)

• Ranitidine (withdrawn), Famotidine: Used pre-PPI era
• Less effective; required very high doses (e.g., famotidine 800 mg/day)
• Tachyphylaxis (loss of efficacy) common

Somatostatin Analogues

Indications:

1. Tumor growth suppression (antiproliferative effect)
2. Adjunct acid control in PPI-refractory cases
3. Symptomatic control of metastatic disease

Agents:

• Octreotide LAR: 20–30 mg IM every 4 weeks

• Lanreotide Autogel: 120 mg SC every 4 weeks

• Inhibits gastrin release and gastric acid secretion

• Stabilizes tumour growth in 30–50% of advanced NETs [24]

• Side effects: Cholelithiasis (30%), diarrhea (paradoxically), hyperglycemia

Surgical Management

Goal: Complete tumour resection (curative in sporadic, localized disease)

Indications for Surgery

1. Sporadic gastrinoma (no MEN1)
2. Localized disease (no distant metastases)
3. Fit for surgery (good performance status)

Contraindications / Relative Contraindications

• MEN1-associated gastrinoma: Usually multiple microadenomas; cure rare (less than 10%); surgery reserved for dominant tumour > 2 cm or rapid growth [25]
• Diffuse liver metastases: Surgery not curative; medical management preferred
• Poor surgical candidate: Comorbidities, advanced age

Surgical Approaches

1. Duodenotomy with Careful Palpation and Enucleation:

   • For duodenal gastrinomas (less than 1 cm, submucosal)
   • Duodenum opened longitudinally; palpation + transillumination to identify small tumours
   • Enucleation of duodenal tumours [26]

2. Pancreatic Resection:

   • Enucleation: If tumour less than 2 cm, located in periphery of pancreas
   • Distal Pancreatectomy: For body/tail tumours
   • Whipple Procedure (Pancreaticoduodenectomy): For large pancreatic head tumours (rare)

3. Regional Lymphadenectomy:

   • Peripancreatic and periduodenal lymph nodes
   • 10% of "gastrinomas" are primary nodal tumours [7]

Outcomes of Surgery

• Cure Rate (Sporadic):
  • "Immediate post-op biochemical cure (normogastrinemia): 60–70%"
  • 10-year disease-free survival: 30–40% [27]
• Cure Rate (MEN1): less than 10% (due to multiplicity of tumours)
• Recurrence: 30–50% within 5–10 years (often due to missed microadenomas or nodal disease)

Management of Metastatic/Advanced Disease

Liver-Directed Therapies

1. Surgical Debulking / Metastasectomy:

   • If ≥90% tumour burden removable
   • Improves hormonal control, prolongs survival

2. Radiofrequency Ablation (RFA) or Microwave Ablation:

   • For limited liver metastases (less than 3 lesions, less than 3 cm)

3. Transarterial Embolization (TAE) / Chemoembolization (TACE):

   • For symptomatic liver metastases
   • Devascularizes tumours; liver receives dual blood supply (hepatic artery + portal vein), tolerates embolization

Peptide Receptor Radionuclide Therapy (PRRT)

• Lutetium-177 DOTATATE (Lutathera®):
  • Radioligand therapy targeting SSTR2
  • Four cycles of 7.4 GBq every 8 weeks
  • "Objective response rate: 20–30%; disease stabilization: 70%"
  • Improved progression-free survival in advanced GEP-NETs [28]

Systemic Chemotherapy

• Indications: Poorly differentiated NETs (grade 3), rapid progression
• Regimens:
  • Streptozocin + 5-Fluorouracil (5-FU)
  • Temozolomide + Capecitabine
• Efficacy: Modest (response rates 30–40%) in well-differentiated NETs; higher in grade 3 tumours

mTOR Inhibitors

• Everolimus (Afinitor®): 10 mg PO daily
• Inhibits mTOR pathway, suppresses tumour proliferation
• Progression-free survival benefit of ~5 months in advanced pancreatic NETs [29]

Long-Term PPI Safety Considerations (2023–2025 Updates)

Emerging Concerns:

• Hypomagnesemia: Occurs in 1–5% of chronic PPI users; may require IV magnesium supplementation or gastrectomy in refractory ZES cases [38]
• Vitamin B12 Deficiency: 21% incidence in long-term ZES patients on PPIs (mean 10 years); correlates with drug-induced achlorhydria (pH \u003e 4). Oral crystalline B12 supplementation (in multivitamins) prevents deficiency [39]
• Fracture Risk: Meta-analyses show 1.3-fold increased hip fracture risk; recommend DEXA screening in long-term users [40]
• Chronic Kidney Disease: Observational data suggest association; monitor renal function annually [41]
• Dementia: Controversial; recent large RCT showed no increased risk [42]
• Gastric Fundic Gland Polyps: Develop in 30–50% of chronic PPI users; benign, no malignant potential [43]

Mitigation Strategies:

• Annual monitoring: Magnesium, vitamin B12, calcium, eGFR
• Bone density screening every 2–5 years in postmenopausal women/men \u003e 50 years
• Oral multivitamin containing B12 and calcium for all long-term users
• Consider dose reduction if acid control allows (titrate with BAO or endoscopic assessment)

---

Emerging Therapies and Recent Advances

K+-Competitive Acid Blockers (P-CABs):

• Vonoprazan: Novel potassium-competitive acid blocker approved in some jurisdictions
• Faster acid suppression than PPIs (within 1 hour vs. 3–5 days for full PPI effect)
• Longer duration of action (up to 72 hours)
• pH-independent activation (unlike PPIs)
• Potential role in PPI-refractory cases or PPI-intolerant patients (e.g., hypomagnesemia)
• Limited published data in ZES patients; case reports suggest efficacy [33]

Novel Diagnostic Approaches:

• Dual-tracer PET imaging: Combining Ga-68 DOTATATE with FDG-PET to assess tumor aggressiveness
• Circulating tumor DNA (ctDNA): Emerging as a potential biomarker for tumor burden and recurrence monitoring
• Liquid chromatography-mass spectrometry (LC-MS): More accurate gastrin assay, reducing false positives [34]

Advanced Liver-Directed Therapies:

• Selective Internal Radiation Therapy (SIRT): Yttrium-90 radioembolization for liver-dominant metastatic disease
• Response rates 30–40% in selected NET patients
• Emerging as alternative to TACE for unresectable liver metastases [35]

Immunotherapy and Targeted Agents:

• Checkpoint Inhibitors: Limited efficacy in well-differentiated NETs due to low tumor mutational burden
• PD-1/PD-L1 inhibitors under investigation in poorly differentiated grade 3 tumours
• VEGF/FGFR Inhibitors: Cabozantinib, lenvatinib showing promise in refractory pancreatic NETs [36]
• Combination Therapies: PRRT + everolimus or PRRT + chemotherapy under investigation [37]

---

8. Complications

Ulcer-Related Complications

Oesophageal Complications

• Erosive Oesophagitis: Universal if untreated
• Peptic Stricture: 10–15%; dysphagia; requires dilatation
• Barrett's Oesophagus: Increased risk; requires surveillance endoscopy

Malignancy and Metastatic Disease

• Metastases:
  • "Liver (most common): 30–40% at diagnosis"
  • "Bone: 10–15%"
  • "Lung, peritoneum: Rare"
• Carcinoid Heart Disease: Rare in gastrinomas (more common in midgut carcinoids)

ECL Cell Hyperplasia and Gastric Carcinoids

• Chronic hypergastrinemia → ECL cell proliferation → Type 2 gastric carcinoid NETs (in MEN1-associated ZES)
• Usually small, multiple, indolent
• Annual surveillance endoscopy recommended in MEN1 patients [14]

Treatment-Related Complications

• PPI-Associated: Hypomagnesemia, osteoporosis, C. difficile infection
• Octreotide-Associated: Cholelithiasis (30%), glucose intolerance
• Surgical: Pancreatic fistula (5–10% post-pancreatic resection), exocrine insufficiency, diabetes

---

9. Prognosis and Outcomes

Survival

Sporadic Gastrinoma:

• 5-Year Survival:
  • "Localized disease: 90–95%"
  • "Liver metastases: 60–70%"
  • "Bone metastases: 20–30%"
• 10-Year Survival: 50–60% (all stages combined) [30]

MEN1-Associated Gastrinoma:

• 10-Year Survival: 75–85%
• Better prognosis than sporadic, despite lower cure rates
• Death often from MEN1-related complications (hyperparathyroidism, pituitary tumours) rather than gastrinoma itself [9]

Prognostic Factors

Favorable:

• Sporadic (vs. MEN1)
• Localized disease (vs. metastatic)
• Tumour size less than 2 cm
• Duodenal location (vs. pancreatic)
• Biochemical cure post-surgery

Unfavorable:

• Liver metastases
• Tumour size > 3 cm
• Pancreatic primary
• High Ki-67 index (> 10%)
• Poorly differentiated histology (grade 3)

Natural History

• Gastrinomas are slowly growing NETs
• Tumour doubling time: 3–10 years
• Death from gastrinoma per se is rare in the modern PPI era (acid hypersecretion well-controlled)
• Death typically from metastatic disease burden, liver failure, or MEN1-related causes

---

10. Prevention & Screening

Primary Prevention

• No established primary prevention strategies (etiology of sporadic gastrinomas unknown)
• MEN1 patients: Genetic counseling; cascade family screening

Screening Recommendations

MEN1 Patients (high risk of gastrinoma):

• Annual fasting gastrin from age 10–15 years
• Secretin stimulation test if gastrin 110–1000 pg/mL
• MRI/CT abdomen or Ga-68 DOTATATE PET if biochemically positive [9]

General Population:

• No screening recommended (very low incidence)
• High clinical suspicion if:
  • Multiple or refractory peptic ulcers
  • Post-bulbar or jejunal ulcers
  • Diarrhea + peptic ulcer disease
  • Family history of MEN1

---

11. Key Guidelines and Evidence

Major Guidelines

Landmark Evidence

1. Berna et al. (2006) – Medicine (Baltimore):

   • Prospective NIH study of 293 ZES patients
   • Secretin stimulation test sensitivity 94%, specificity 100%
   • Established ≥120 pg/mL rise as diagnostic criterion [6]

2. Norton et al. (2018) – Endocrinol Metab Clin North Am:

   • Surgical cure rates: 60–70% in sporadic, less than 10% in MEN1
   • Emphasized individualized approach: surgery for sporadic, medical for MEN1 [25]

3. Ito et al. (2013) – Curr Opin Gastroenterol:

   • Review of ZES controversies: PPI use complicating diagnosis; need for prolonged PPI cessation pre-testing [5]

4. Rossi et al. (2021) – World J Gastroenterol:

   • Comprehensive review of gastrinoma management: acid control, imaging, surgery, and emerging therapies (PRRT) [32]

5. Strosberg et al. (2017) – JAMA Oncol:

   • NETTER-1 trial: Lu-177 DOTATATE significantly improved PFS in midgut NETs (applicable principles to gastrinomas) [28]

---

12. Patient and Layperson Explanation

What is Zollinger-Ellison Syndrome?

Imagine your stomach as a factory that produces acid to digest food. Normally, acid production is tightly controlled—it increases when you eat and stops when you don't need it.

In Zollinger-Ellison Syndrome (ZES), a small growth called a gastrinoma (usually the size of a grape or smaller) produces a hormone called gastrin non-stop. Gastrin is the "ON switch" for acid production. Because the gastrinoma never stops making gastrin, your stomach factory runs 24/7 at full speed, pouring out massive amounts of strong acid.

Why Do I Have Ulcers?

The stomach and intestine normally have protective linings that handle acid well. But in ZES, the acid is so strong and constant that it burns through these linings, creating deep, painful sores called ulcers—like acid burning a hole in fabric.

These ulcers often appear in unusual places (not just the stomach, but also the first part of the intestine called the duodenum, and sometimes even further down in the small intestine). They don't heal with normal ulcer medications because the underlying cause (too much acid) is still there.

Why Do I Have Diarrhea?

When the massive amount of acid floods from your stomach into your intestine, it's like pouring battery acid into a delicate system. The acid:

1. Destroys enzymes (like lipase) that normally digest fats → Fats pass through undigested → Greasy, smelly diarrhea (steatorrhea)
2. Damages the intestinal lining → Fluid leaks into the intestine → Watery diarrhea

In some people, diarrhea is the only symptom, which can be confusing and mistaken for irritable bowel syndrome (IBS) or food intolerance.

How is ZES Diagnosed?

1. Blood Test: Measures gastrin levels. In ZES, gastrin is very high (often 10× normal).
2. Secretin Test: A special test where we give you a hormone called secretin. In healthy people, secretin stops gastrin production. In ZES, the gastrinoma "misbehaves" and secretin makes it produce more gastrin—a paradoxical response that confirms the diagnosis.
3. Scan: A PET scan (Ga-68 DOTATATE) lights up the gastrinoma like a beacon, helping us find it—even if it's tiny.

How is ZES Treated?

1. Stop the Acid (Medical Treatment):

• We give you very high doses of acid-blocking medications (called PPIs, like omeprazole or lansoprazole)—much higher than for normal heartburn.
• This stops the pain and diarrhea immediately in 90–95% of patients.
• You may need to take these medications for life if surgery isn't an option.

2. Remove the Gastrinoma (Surgery):

• If the gastrinoma is single and localized, a surgeon can remove it and cure you.
• Success rate: 60–70% of patients are cured.
• If the gastrinoma is in multiple spots (common in a genetic condition called MEN1) or has spread to the liver, surgery is less likely to cure, but medical treatment still works very well.

3. Advanced Treatments (If Spread):

• If the gastrinoma has spread (metastasized), we use:
  • "Radioactive "smart bomb" therapy (PRRT): Delivers radiation directly to tumour cells"
  • Liver-directed treatments (ablation, embolization)
  • Medications that slow tumour growth (everolimus, somatostatin analogues)

What Can I Expect?

• With treatment, most people live normal, symptom-free lives.
• Prognosis: Even if the gastrinoma can't be completely removed, it grows very slowly (like a snail, not a racehorse). With modern treatments, 10-year survival is 75–90%.
• Monitoring: You'll need regular check-ups, blood tests, and scans to monitor the gastrinoma and make sure treatment is working.

---

13. Examination Focus

Common MRCP/FRACP Questions

1. "A 35-year-old man has recurrent duodenal ulcers despite high-dose PPI. Fasting gastrin is 800 pg/mL. What is the next step?"

   • Answer: Measure gastric pH (confirm acid hypersecretion) and perform secretin stimulation test. Exclude PPI-induced hypergastrinemia (ensure 2-week PPI cessation before retesting).

2. "What is the most common location of a gastrinoma?"

   • Answer: Duodenum (50–60% of cases), often within the gastrinoma triangle. Pancreas is second (25–40%).

3. "A patient with ZES has multiple gastrinomas. Which syndrome should be considered?"

   • Answer: MEN1 (Multiple Endocrine Neoplasia Type 1). Screen for hyperparathyroidism (calcium, PTH), pituitary adenomas (prolactin), and other pancreatic NETs.

4. "What is the mechanism of diarrhea in ZES?"

   • Answer: Massive acid output → Low intraduodenal pH → Inactivates pancreatic lipase → Fat malabsorption (steatorrhea) + osmotic/secretory diarrhea.

5. "Which imaging modality is the gold standard for localizing gastrinomas?"

   • Answer: Ga-68 DOTATATE PET/CT (somatostatin receptor imaging). Sensitivity 90–95% for primary tumours and metastases.

Viva Points

Opening Statement:
"Zollinger-Ellison Syndrome is a clinical syndrome caused by a gastrin-secreting neuroendocrine tumour (gastrinoma), resulting in severe gastric acid hypersecretion. It is characterized by refractory peptic ulcer disease, often in unusual locations, diarrhea, and severe GERD. The majority of cases are sporadic (75–80%), but 20–25% are associated with MEN1."

Key Facts to Memorize:

• Incidence: 0.5–2 per million per year
• Gastrinoma Triangle: Bounded by cystic duct, D2/D3 junction, pancreatic neck
• Secretin test sensitivity: 94%; criterion: ≥120 pg/mL rise
• Cure rate (sporadic): 60–70%; cure rate (MEN1): less than 10%
• 60–90% of gastrinomas are malignant, but slow-growing
• First-line acid control: High-dose PPI (e.g., omeprazole 60 mg BD)

Examiner Follow-Up Questions & Model Answers:

Q: "Why do PPIs need to be stopped before testing for ZES?"
A: "PPIs induce achlorhydria (low acid), which causes a reactive rise in gastrin via loss of negative feedback. This mimics ZES biochemically (hypergastrinemia) but with high gastric pH (> 4), unlike true ZES where pH is low (less than 2). Stopping PPIs for 2 weeks allows gastrin levels to normalize if PPI-induced."

Q: "Are gastrinomas benign or malignant?"
A: "60–90% are malignant, defined by presence of metastases (liver, lymph nodes, bone). However, they are 'indolent'—slow-growing NETs with doubling times of 3–10 years. Even with liver metastases, 10-year survival is 60–70%, largely due to effective acid suppression with PPIs preventing ulcer-related mortality."

Q: "Why is surgery not curative in MEN1-associated ZES?"
A: "MEN1 patients typically have multiple microadenomas (less than 1 cm) scattered throughout the duodenum and pancreas, making complete surgical resection impossible. Cure rates are less than 10%, compared to 60–70% in sporadic (usually single tumour) cases. Management focuses on high-dose PPI therapy and surveillance."

Common Exam Mistakes

❌ Missing the diagnosis because patient is on PPIs and asymptomatic (symptoms masked)
✅ Correct approach: Maintain high index of suspicion for refractory ulcers, unusual ulcer locations, or diarrhea + PUD

❌ Failing to stop PPIs before testing → False-positive hypergastrinemia
✅ Correct approach: 2-week PPI cessation; measure gastrin + gastric pH

❌ Assuming high gastrin = ZES without checking gastric pH
✅ Correct approach: Hypergastrinemia + low pH (less than 2) = ZES; hypergastrinemia + high pH (> 4) = achlorhydria (atrophic gastritis, PPI use)

❌ Assuming gastrinomas are benign (because "slow-growing")
✅ Correct approach: 60–90% are malignant; metastases in 30–40% at diagnosis

---

14. References

Primary Sources

1. Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29(6):650-661. doi:10.1097/MOG.0b013e328365efb1

2. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98-119. doi:10.1159/000335591

3. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. doi:10.1210/jc.2012-1230

4. Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol. 2012;18(39):5495-5503. doi:10.3748/wjg.v18.i39.5495

5. Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2013;14(3):307-321. doi:10.1517/14656566.2013.767332

6. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Medicine (Baltimore). 2006;85(6):331-364. doi:10.1097/MD.0b013e31802b518c

7. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341(9):635-644. doi:10.1056/NEJM199908263410902

8. Maton PN. Omeprazole. N Engl J Med. 1991;324(14):965-975. doi:10.1056/NEJM199104043241407

9. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2):2-15. doi:10.1016/j.mce.2013.08.002

10. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6(6):454-463. doi:10.1007/s11894-004-0067-5

11. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000;79(6):379-411. doi:10.1097/00005792-200011000-00004

12. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842-1860. doi:10.1053/j.gastro.2008.05.021

13. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295-330. doi:10.1097/01.md.0000236956.74128.76

14. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395-401. doi:10.1007/s00428-006-0250-1

15. Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212-244. doi:10.1159/000471879

16. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108(6):1637-1649. doi:10.1016/0016-5085(95)90124-8

17. Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology. 2004;80 Suppl 1:23-27. doi:10.1159/000080735

18. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3(1):39-48. doi:10.1016/s1542-3565(04)00607-5

19. Goldman JA, Blanton WP, Hay DW, Wolfe MM. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009;7(5):600-602. doi:10.1016/j.cgh.2009.02.018

20. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967-1973. doi:10.1200/JCO.2006.10.1535

21. Rösch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326(26):1721-1726. doi:10.1056/NEJM199206253262601

22. Imamura M, Takahashi K, Adachi H, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg. 1987;205(3):230-239. doi:10.1097/00000658-198703000-00003

23. Metz DC, Pisegna JR, Fisbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103(5):1498-1508. doi:10.1016/0016-5085(92)91171-7

24. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510

25. Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am. 2018;47(3):577-601. doi:10.1016/j.ecl.2018.04.009

26. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234(4):495-505. doi:10.1097/00000658-200110000-00009

27. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):757-773. doi:10.1097/01.sla.0000143252.02142.3e

28. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427

29. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523. doi:10.1056/NEJMoa1009290

30. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17(2):615-630. doi:10.1200/JCO.1999.17.2.615

31. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-171. doi:10.1159/000443171

32. Rossi RE, Elvevi A, Citterio D, et al. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol. 2021;27(35):5890-5907. doi:10.3748/wjg.v27.i35.5890

33. Chatzipanagiotou O, Schizas D, Vailas M, et al. All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update. J Neuroendocrinol. 2023;35(4):e13267. doi:10.1111/jne.13267

34. Jensen RT, Ramos-Alvarez I, Norton JA. Current Medical Controversies in Zollinger–Ellison Syndrome. Biomedicines. 2025;13(12):3051. doi:10.3390/biomedicines13123051

35. Panzuto F, Ramage J, Pritchard DM, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. J Neuroendocrinol. 2023;35(8):e13306. doi:10.1111/jne.13306

36. Lamberti G, Panzuto F, Pavel M, et al. Gastric neuroendocrine neoplasms. Nat Rev Dis Primers. 2024;10(1):25. doi:10.1038/s41572-024-00506-8

37. Massironi S, Rossi RE, Laffusa A, et al. Sporadic and MEN1-related gastrinoma and Zollinger-Ellison syndrome: differences in clinical characteristics and survival outcomes. Dig Liver Dis. 2024;56(8):1342-1349. doi:10.1016/j.dld.2024.02.009

38. Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep. 2019;21(4):13. doi:10.1007/s11894-019-0681-1

39. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27(11):1110-1121. doi:10.1111/j.1365-2036.2008.03658.x

40. Zhou B, Huang Y, Li H, et al. Proton pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339-347. doi:10.1007/s00198-015-3365-x

41. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-246. doi:10.1001/jamainternmed.2015.7193

42. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35-48. doi:10.1053/j.gastro.2017.04.047

43. Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. doi:10.1186/s12916-016-0718-z

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.